Axcella Health Inc AXLA

Healthcare Biotechnology

Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.

PINL:AXLA - Post by User

Axcella Health Inc > AXLA ..... LOve it ....sold to Am,erica

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Sep 13, 2023 2:26pm

14 Views

Post# 35634372

RE:AXLA ..... LOve it ....sold to Am,erica

In hindsight.... I Might have left some on the table..... but now I'm looking like a a Champ

I never cry over spilled stocks

Just take what the market gives

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions